Open AccessNevirapine- Versus Lopinavir/Ritonavir-Based Initial Therapy for HIV-1 Infection among Women in Africa: A Randomized Trial
Author(s) -
Shahin Lockman,
Michael D. Hughes,
Fred Sawe,
Yu Zheng,
James McIntyre,
Tsungai Chipato,
Aida Asmelash,
Mohammed Rassool,
Sylvester Kimaiyo,
Douglas Shaffer,
Mina C. Hosseinipour,
Lerato Mohapi,
Francis Ssali,
Margret C. Chibowa,
Farida Amod,
Elias K. Halvas,
Evelyn Hogg,
Beverly AlstonSmith,
Laura Smith,
Robert T. Schooley,
John W. Mellors,
Judith S. Currier,
the OCTANE (Optimal Combination Therapy After Nevirapine Exposure) ACTG AOCTANE Study Team
Publication year - 2012
Publication title -
plos medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.847
H-Index - 228
eISSN - 1549-1676
pISSN - 1549-1277
DOI - 10.1371/journal.pmed.1001236
Subject(s) - nevirapine , medicine , lopinavir , lopinavir/ritonavir , emtricitabine , randomized controlled trial , ritonavir , clinical endpoint , lamivudine , hazard ratio , viral load , surgery , human immunodeficiency virus (hiv) , immunology , antiretroviral therapy , confidence interval , hepatitis b virus , virus
In a randomized control trial, Shahin Lockman and colleagues compare nevirapine-based therapy with lopinavir/ritonavir-based therapy for HIV-infected women without previous exposure to antiretroviral treatment.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom